NASDAQ:CRSP

Crispr Therapeutics Stock News

etoro logo Buy CRSP
*Your capital is at risk
$46.99
-0.790 (-1.65%)
At Close: Jul 20, 2026

The Best Stocks to Invest $1,000 in Right Now

04:17am, Tuesday, 24'th Jun 2025
Is it time to reload your portfolio with some new picks? That's easier said than done right now.

The Big 3: CRSP, OKLO, GME

12:01pm, Monday, 23'rd Jun 2025
Mike Shorr (@ProsperTradingAcademy) looks to manage risk levels in his 3 example options trades. For Crispr Therapeutics (CRSP), he's looking at low-implied volatility in the gene-editing biotech comp
If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates
CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $44.43, representing a +2.87% change from its previous close.
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRSP's innovative pipeline shines, but the biotech does face regulatory risks and fierce competition.
Crispr Therapeutics AG is transitioning to a commercial company, with CASGEVY's rollout and a robust pipeline in cardiovascular, autoimmune, and oncology driving long-term potential. The cardiovascula
Biotech stock Crispr Therapeutics Inc's (NASDAQ:CRSP) June rally appears to be coming to an end.
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $42.94, representing a +2.02% change from its previous close.
CRISPR Therapeutics AG (NASDAQ:CRSP ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 3:20 PM ET Company Participants Samarth Kulkarni - CEO & Chairman Conference Call Participants
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE